Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Companies

Management changes at Seattle Genetics

This article was originally published in Scrip

  • Zoë Dann

Executive Summary

Bruce Seeley has been appointed executive vice-president of commercial at Seattle Genetics (US). He has more than 18 years' experience in oncology drug marketing and sales, having most recently served as senior director for Herceptin (trastuzumab) and T-DM1 marketing at Genentech (Roche). Seattle Genetics has also promoted its general counsel Kirk Schumacher to the additional role of vice-president of legal affairs and compliance.

Table

View full table

Topics

Related Companies

Tags:
Companies
Latest Headlines

Obesity Gold Rush To Drive Significant Spending Growth Through Decade, IQVIA Says

With Vertex Pain Drug Filed At FDA, Commercial Ramp Is Under Way

Zenas Raises $200m For Bifunctional Antibody In Autoimmune Diseases

BioNTech Ramps Up Spending To Launch 10 Pivotal Cancer Studies In 2024

See All
UsernamePublicRestriction

Register

SC005077

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By